Potency of drug combinations in diabetic neuropathic pain

Primary tabs

NEWS
Potency of drug combinations in diabetic neuropathic pain

Every one in five patients suffer from diabetic neuropathy and it is associated with diabetes. There is no single treatment option to avoid or reverse neuropathic changes or to provide overall pain relief. It has been believed that diabetic neuropathy represents an ongoing therapeutic challenge for patients and caregivers. About 39% cases of PDN remained untreated. This experimental validation study was performed to perceive the effect of amitripyline, duloxetine, sitagliptin, and pregabalin, and their combinations on streptozotocin (STZ)-induced diabetic neuropathy. In 2004, duloxetine and pregabalin were approved by the US Food and Drug Administration (FDA) for management of this illness.

Diabetic  neuropathy was instigated by STZ, and the tail-flick test was used to analyse the thermal hyperalgesia before and after (at 30, 60, and 120 min) drug administration. After one week of STZ administration, blood glucose level was noticed to be in the diabetic range.

As per the outcomes obtained, the administration of  all drugs other than sitagliptin surged the tail-flick latency significantly as compared to control. Also, the drugs amitriptyline, duloxetine, and pregabalin revealed significant pain-relieving effect, when either two of them were employed in combination, although the varied combinations had varied degree of pain relief. There was no change spotted out when sitagliptin was used alone or in combination with the other three drugs.

It can be concluded that this study provides new perceptions related to combined therapy of pain, which further requires clinical exploration.

J Basic Clin Physiol Pharmacol.
Log in or register to post comments